 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
49 News |  |
- Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Developing a stimulation-free remote motor unit number estimate in Motor Neurone Disease (REMUNE) (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 20, 2024 - Abstract #ALSMND2024ALS_MND_762;
- Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Developing a stimulation-free Remote Motor Unit Number Estimate (Remune) (Event Halle, Messe Basel, Ground Floor) - Nov 7, 2023 - Abstract #ALSMND2023ALS_MND_329;
- || Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Trial completion, Enrollment change: Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia (clinicaltrials.gov) - Aug 15, 2023
P1, N=25, Completed, Sponsor: University of Rochester
Active, not recruiting --> Completed | N=45 --> 25
- | Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Trial completion date: Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia (clinicaltrials.gov) - Aug 14, 2023
P1, N=45, Active, not recruiting, Sponsor: University of Rochester
Active, not recruiting --> Completed | N=45 --> 25 Trial completion date: Dec 2023 --> Dec 2025
- || Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Enrollment closed, Trial completion date, Trial primary completion date: Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia (clinicaltrials.gov) - Jun 9, 2022
P1, N=45, Active, not recruiting, Sponsor: University of Rochester
Trial completion date: Dec 2023 --> Dec 2025 Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
- |||| Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
FDA event: I'm probably the greatest American to ever live first I got First #HIV Vaccine #Remune filed for FDA approval w rotten @FDA it's like rotten apples over there like planet of Apes all that security LOL WTF are they guarding over there SMH No one can do anything about generic drug (Twitter) - Apr 4, 2021
- || Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Enrollment open: Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia (clinicaltrials.gov) - Jun 4, 2020
P1, N=45, Recruiting, Sponsor: University of Rochester
Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Apr 2023 Not yet recruiting --> Recruiting
- | Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Trial completion date, Trial primary completion date: Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia (clinicaltrials.gov) - Mar 3, 2020
P1, N=45, Not yet recruiting, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Apr 2022
- | Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
New P1 trial: Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia (clinicaltrials.gov) - Oct 17, 2019
P1, N=45, Not yet recruiting, Sponsor: University of Rochester
- || Remune (gp 120-depleted HIV-1) / Orchestra
Dois pontos à se considerar nesta matéria: 1. Ter uma Remune 2. Ampliar a oferta de medicamentos na Remune considerando critérios técnicos, sem extrapolar a RENAME. Parabéns a POA. Uma sugestão que tivemos uma experiência bacana, CURAMEs para avaliação do processo de incoporação. (Twitter) - Aug 2, 2019
- ||||| Remune (gp 120-depleted HIV-1) / Immune Response BioPharma, RemuneX (IR103) / Immune Response BioPharma
P3 data: RAISE: REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study (clinicaltrials.gov) - Feb 23, 2016
P3, N=500, Not yet recruiting, Sponsor: Immune Response BioPharma, Inc.
Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Apr 2022 Initiation date: Jun 2016 --> Jun 2017 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Trial initiation date, Trial primary completion date: REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study (clinicaltrials.gov) - Feb 23, 2016
P2, N=26, Not yet recruiting, Sponsor: Immune Response BioPharma, Inc.
Initiation date: Jun 2016 --> Jun 2017 | Trial primary completion date: Jun 2018 --> Jun 2019 Initiation date: Nov 2016 --> Nov 2017 | Trial primary completion date: Nov 2018 --> Nov 2019
- |||||||||| Remune (gp 120-depleted HIV-1) / Immune Response BioPharma, RemuneX (IR103) / Immune Response BioPharma
P3 data: RAISE: REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study (clinicaltrials.gov) - Feb 19, 2015
P3, N=500, Not yet recruiting, Sponsor: Immune Response BioPharma, Inc.
- | Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Trial initiation date, Trial primary completion date: REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study (clinicaltrials.gov) - Feb 11, 2015
P2, N=26, Not yet recruiting, Sponsor: Immune Response BioPharma, Inc.
Initiation date: Nov 2016 --> Nov 2017 | Trial primary completion date: Nov 2018 --> Nov 2019 Initiation date: Sep 2015 --> Nov 2016 | Trial primary completion date: Sep 2017 --> Nov 2018
- | Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
New P2 trial: REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study (clinicaltrials.gov) - Nov 14, 2014
P2, N=26, Not yet recruiting, Sponsor: Immune Response BioPharma, Inc.
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452 (clinicaltrials.gov) - Feb 19, 2014
P1, N=80, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Sep 2015 --> Nov 2016 | Trial primary completion date: Sep 2017 --> Nov 2018 No longer recruiting --> Completed
- | ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
Trial completion: Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination (clinicaltrials.gov) - Feb 19, 2014
P3, N=472, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed No longer recruiting --> Completed
- Remune (gp 120-depleted HIV-1) / Immune Response BioPharma
Trial completion: Combination Vaccination Before HIV Treatment Interruption (clinicaltrials.gov) - May 21, 2012
P1/2, N=60, Completed, Sponsor: Ottawa Hospital Research Institute
No longer recruiting --> Completed Active, not recruiting --> Completed